Episode 119 of the NeurologyLiveMind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service. Continue reading →

Washington, D.C. Continue reading →

West Virginia has the third-highest prevalence rate of Parkinsons in the country with about 7,000 people living with the disease, according to the Economic Burden of Parkinsons Disease study published in 2019. Continue reading →

Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinsons disease, and improved cognition in those with mild dementia. Thats according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio, also improved motor function in patients with a diagnosis more than three years prior, as well as in those with postural instability and gait difficulties. We are very pleased to see improvements in many of our patients over such a short course of treatment, Maria Maccecchini, PhD, founder, president, and CEO of Annovis Bio, said in a company press release. Continue reading →

The progressive neurodegenerative condition affects around 153,000 people in the UK Mission Therapeutics has been awarded $5.2m in funding from Parkinsons UKs Virtual Biotech programme and the Michael J. Fox Foundation to advance a potential treatment for early-stage Parkinsons disease (PD) Continue reading →

BEACHWOOD, Ohio Just past the shadows of Cleveland Browns Stadium, Beachwood's InMotion offers a sense of community for people living with Parkinson's disease. "There's a misconception about Parkinson's out there," said Cathe Schwartz, CEO of InMotion. "I think Parkinson's still has a stigma." But Schwartz said the reality is people can live productive, positive lives with the nervous system disease. Continue reading →

The first three Parkinsons disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12 adults with a diagnosis of Parkinsons for five or more years received a single transplant of TED-A9, at either a low or high dose, directly into the brain. The clinical results demonstrated very promising efficacy, Dong-Wook Kim, MD, PhD, a professor at Yonsei University College of Medicine in Seoul, South Korea, and chief technology officer at S.Biomedics, said in a company press release. Continue reading →

Clumps of RNA-binding proteins have been discovered in the nucleus of nerve cells derived from people with Parkinsons disease, according to a new study. Continue reading →

AskBios investigational gene therapy AB-1005 has been granted fast-track designation for Parkinsons disease by the U.S. Food and Drug Administration (FDA), and innovation passport designation by the regulatory agency in the U.K. These designations are meant to accelerate the development and review process of therapy candidates designed to treat serious conditions and fill unmet clinical needs, which may offer significant benefits over approved treatments Continue reading →

WATCH TIME: 5 minutes "I think one of the biggest things I've learned in this study is that 100% of everyone has the patient's care and the best interest of the patient at heart, and so people are really receptive." A relatively new concept, the Cleveland Clinic (CCF)s Parkinsons Inpatient Program implements system and patient-level interventions to enhance recovery for patients with Parkinson disease (PD). At the enterprise level of the program, modifications were made to electronic health records, including best practice alerts and notifications for PD contraindicated medications. Continue reading →